Treatment of the neuropsychiatric symptoms in Alzheimer's disease.
Masterman
Donna
D
Department of Neurology, David Geffen School of Medicine at University of California at Los Angeles, USA. donnam@amgen.com
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D017028:Caregivers / Q000592:standards; D002795:Choline O-Acetyltransferase / Q000172:deficiency* / Q000378:metabolism; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000209:etiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D012725:Sexual Behavior / Q000187:drug effects; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy / Q000209:etiology; D014481:United States
D000319:Adrenergic beta-Antagonists; D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D002795:Choline O-Acetyltransferase; D017367:Selective Serotonin Reuptake Inhibitors